NCT03236428 2026-03-27
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
19 trialsNCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT03820817 2025-04-20
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
Phase 1 Active not recruiting
NCT01186224 2025-03-17
PHANTASTIC
University of Liverpool
Phase NA Completed
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT05280275 2023-12-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Phase 1/2 Unknown
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT03591614 2023-08-18
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT05362331 2023-02-09
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
Phase NA Withdrawn
NCT02556931 2022-11-03
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05581875 2022-10-17
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
Phase 1/2 Not yet recruiting
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT01543100 2014-01-06
PACMoG
Rennes University Hospital
Phase NA Completed
NCT01755000 2013-09-02
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
Washington University School of Medicine
Phase NA Completed